SOUTH SAN FRANCISCO, Calif., Oct. 19 /PRNewswire-FirstCall/ -- Renovis, Inc. will announce financial results for the third quarter of 2006 on Thursday, October 26, 2006, after the close of U.S. financial markets. Following the announcement, Renovis will host a conference call at 4:30 p.m. Eastern Time that afternoon to review the company's financial results.
Interested parties may access the call by dialing 1-866-770-7125 in the United States and +1-617-213-8066 internationally. The participant code is 74089409. This call will be webcast and accessible in the Investor Relations section of Renovis' Web site at www.renovis.com . A replay of the Webcast will be available until October 19, 2007.
About Renovis
Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. Our most advanced product candidate, NXY-059, is in Phase III clinical trials for acute ischemic stroke with our exclusive licensee, AstraZeneca AB. NXY-059, which has a proposed mechanism of action of free radical trapping, is being studied as a neuroprotectant in clinical trials based on effects seen in experimental models of acute ischemic stroke. In addition to proprietary research programs in the areas of cytoprotection, pain and inflammation, Renovis has a worldwide collaboration and license agreement with Pfizer to research, develop and commercialize small molecule VR1 antagonists, and a research and development collaboration with Genentech to discover and develop anti-angiogenesis drugs and drugs that promote nerve re-growth following nervous system injury.
For additional information about the company, please visit www.renovis.com .
Renovis, Inc.CONTACT: Greg Mann of Renovis, Inc., +1-650-266-1558, or gmann@renovis.com